2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Glioblastoma
405
Brain Neoplasms
163
Glioma
159
Gliosarcoma
131
Astrocytoma
115
Central Nervous System Neoplasms
110
Melanoma
75
Oligodendroglioma
74
Neuroblastoma
44
Neoplasms
33
Medulloblastoma
33
Neoplasm Metastasis
29
Recurrence
28
Ependymoma
26
Sarcoma
23
Sarcoma, Ewing
22
Rhabdomyosarcoma
18
Small Cell Lung Carcinoma
16
Lymphoma
16
Carcinoma, Non-Small-Cell Lung
16
Diffuse Intrinsic Pontine Glioma
15
Lung Neoplasms
14
Breast Neoplasms
14
Ovarian Neoplasms
13
Neuroendocrine Tumors
13
Choroid Plexus Neoplasms
13
Optic Nerve Glioma
11
Neuroectodermal Tumors, Primitive
11
Spinal Cord Neoplasms
10
Rhabdoid Tumor
10
Interventions
Cyclophosphamide
211
fludarabine phosphate
185
Azacitidine
160
fludarabine
144
Busulfan
140
Tacrolimus
120
Mycophenolic Acid
112
Cytarabine
111
Whole-Body Irradiation
107
Peripheral Blood Stem Cell Transplantation
99
Antilymphocyte Serum
97
Melphalan
91
Filgrastim
87
Cyclosporine
83
Decitabine
82
Methotrexate
79
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
47
Cord Blood Stem Cell Transplantation
43
Clofarabine
42
thymoglobulin
41
Specimen Handling
35
Etoposide
35
Methylprednisolone
34
Sirolimus
33
Biopsy
30
Injections
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Temozolomide
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts